Real Time Optical Coherence Tomography (OCT) of Human Tissue
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01506700|
Recruitment Status : Suspended
First Posted : January 10, 2012
Last Update Posted : February 7, 2018
|Condition or disease||Intervention/treatment|
|Breast Cancer||Device: Optical Coherence Tomography|
This study is a single-center, prospective, two-part open label study of an optical imaging device on approximately twenty (20) subjects at one (1) study site. Patients scheduled to undergo a lumpectomy will be recruited by the clinical investigators at the investigational site in accordance with the inclusion and exclusion criteria. The study period per subject is the time it takes to assess the in vivo and ex vivo breast tissue samples using the study device during their lumpectomy.
All specimens will be marked with India ink and undergo standard post-operative histology, and digital histology images corresponding to the inked locations will be obtained. The images and the matched digitized post-operative histology images will then be randomized and read by a blinded, independent pathologist. Sensitivity and specificity will be calculated.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Real Time Optical Coherence Tomography (OCT) of Human Tissue|
|Study Start Date :||May 2012|
|Estimated Primary Completion Date :||February 2019|
|Study Completion Date :||February 2019|
- Device: Optical Coherence Tomography
Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
- The sensitivity and specificity of Optical Coherence Tomography to identify whether or not tumor can be identified ex vivo on breast cancer specimens as compared to post-surgical histology conclusions. [ Time Frame: One week after surgery ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01506700
|United States, Illinois|
|Carle Foundation Hospital|
|Urbana, Illinois, United States, 61801|
|Study Chair:||Stephen A Boppart, MD, PhD||University of Illinois and Diagnostic Photonics, Inc.|